<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00979745</url>
  </required_header>
  <id_info>
    <org_study_id>CUV029</org_study_id>
    <nct_id>NCT00979745</nct_id>
  </id_info>
  <brief_title>Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)</brief_title>
  <official_title>A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Erythropoietic Protoporphyria (EPP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinuvel Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinuvel Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Afamelanotide is a man-made drug being studied for use as a preventative medication for EPP&#xD;
      sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating&#xD;
      hormone (alpha-MSH) and is not yet available on the market.&#xD;
&#xD;
      The purpose of this study is to look at whether afamelanotide can reduce the number and&#xD;
      severity of EPP symptoms when patients are exposed to light. This study will also look at how&#xD;
      the drug is tolerated when taken by people with EPP.&#xD;
&#xD;
      The study will involve the use of an implant, which comes in the form of a small rod&#xD;
      (approximately 2 cm x 0.15 cm) to be administered under the skin. The implant may contain the&#xD;
      study drug afamelanotide or a placebo (inactive medication).&#xD;
&#xD;
      Over 450 subjects have been treated with afamelanotide to date with no serious safety&#xD;
      concerns identified. For this study, afamelanotide has been formulated as a controlled&#xD;
      release depot injection (implant). This means that the afamelanotide will be released slowly&#xD;
      into the body over a few days. Once inserted, the implant will remain in the body after&#xD;
      afamelanotide has been released and will slowly dissolve.&#xD;
&#xD;
      This study will help to provide more information about afamelanotide. This information will&#xD;
      be used to determine the safety and efficacy (the ability of the drug to produce an effect)&#xD;
      of this drug in EPP sufferers.&#xD;
&#xD;
      Up to 70 people will participate in this study from study sites across Europe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE:&#xD;
&#xD;
      To determine whether afamelanotide can reduce the severity of phototoxic reactions in&#xD;
      patients with EPP.&#xD;
&#xD;
      THEORETICAL FRAMEWORK:&#xD;
&#xD;
      EPP is a genetic photosensitivity disorder where the mainstays of management are covering up&#xD;
      from sunlight, systemic beta carotene and the use of controlled courses of UVR treatment. One&#xD;
      of the mechanisms for the protective effects of UVR treatment is the increase in melanin&#xD;
      content of the skin. UVR treatment causes DNA damage to skin cells and increases the risk for&#xD;
      skin cancers, hence it is unwise for this to be used on a recurring basis. Afamelanotide,&#xD;
      through its ability to stimulate melanin production without causing the DNA damage associated&#xD;
      with UVR treatment, appears to be a promising agent to combat this distressing disorder.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      This is a phase III, randomised, placebo controlled study to evaluate the safety and efficacy&#xD;
      of subcutaneous implants of afamelanotide in patients suffering from EPP. The study will be&#xD;
      performed in compliance with Good Clinical Practice (GCP) including the archiving of&#xD;
      essential documents.&#xD;
&#xD;
      METHODOLOGY:&#xD;
&#xD;
      The target population consists of male and female participants. Up to 70 patients with&#xD;
      diagnosed EPP (from past case history) and fulfilling the necessary inclusion/exclusion&#xD;
      criteria will be enrolled. Potential study patients will be identified from each centre's&#xD;
      records of patients with well characterised history (or documented diagnosis) of EPP.&#xD;
&#xD;
      Patients will be enrolled and will receive afamelanotide (16 mg implants) or placebo&#xD;
      according to the following dosing regime:&#xD;
&#xD;
        -  Group A will be administered active implants on Days 0, 60, 120, 180 and 240.&#xD;
&#xD;
        -  Group B will be administered placebo implants on Days 0, 60, 120, 180 and 240.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)</measure>
    <time_frame>From baseline to Day 270</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Phototoxic Reactions</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measured by Patient Completed Questionnaire</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Protoporphyrin IX Level</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Erythropoietic Protoporphyria</condition>
  <arm_group>
    <arm_group_label>Afamelanotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afamelanotide</intervention_name>
    <description>One 16mg subcutaneous implant every 2 months for 9 months.</description>
    <arm_group_label>Afamelanotide</arm_group_label>
    <other_name>CUV1647</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One 16mg subcutaneous implant every 2 months for 9 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with a diagnosis of EPP (confirmed by elevated free&#xD;
             protoporphyrin in peripheral erythrocytes) of sufficient severity that they have&#xD;
             requested treatment to alleviate their symptoms.&#xD;
&#xD;
          -  Aged 18 - 70 years (inclusive)&#xD;
&#xD;
          -  Written informed consent prior to the performance of any study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any allergy to afamelanotide or the polymer contained in the implant or to lignocaine&#xD;
             or other local anaesthetic to be used during the administration of study medication.&#xD;
&#xD;
          -  EPP patients with significant hepatic involvement.&#xD;
&#xD;
          -  Personal history of melanoma or dysplastic nevus syndrome.&#xD;
&#xD;
          -  Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other&#xD;
             malignant or premalignant skin lesions.&#xD;
&#xD;
          -  Any other photodermatosis such as PLE, DLE or solar urticaria.&#xD;
&#xD;
          -  Any evidence of clinically significant organ dysfunction or any clinically significant&#xD;
             deviation from normal in the clinical or laboratory determinations.&#xD;
&#xD;
          -  Acute history of drug or alcohol abuse (in the last 12 months).&#xD;
&#xD;
          -  Patient assessed as not suitable for the study in the opinion of the Investigator&#xD;
             (e.g. noncompliance history, allergic to local anaesthetics, faints when given&#xD;
             injections or giving blood).&#xD;
&#xD;
          -  Female who is pregnant (confirmed by positive serum Î²-HCG pregnancy test prior to&#xD;
             baseline) or lactating.&#xD;
&#xD;
          -  Females of child-bearing potential (pre-menopausal, not surgically sterile) not using&#xD;
             adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide,&#xD;
             intrauterine device).&#xD;
&#xD;
          -  Sexually active men with partners of child bearing potential not using barrier&#xD;
             contraception during the trial and for a period of three months thereafter.&#xD;
&#xD;
          -  Participation in a clinical trial of an investigational agent within 30 days prior to&#xD;
             the screening visit.&#xD;
&#xD;
          -  Prior and concomitant therapy with medications which may interfere with the objectives&#xD;
             of the study, including drugs that cause photosensitivity or skin pigmentation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Anstey, MBBS, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Woolos Hospital, Newport</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Frank, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raili Kauppinen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Central Hospital of Helsinki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric JG Sijbrands, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Charles Deybach, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Francais des Porphyries, Hopital Louis Mourier, Colombes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Hanneken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine UniversitÃ¤t, DÃ¼sseldorf, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gillian M Murphy, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaumont Hospital, Dublin, Ireland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lesley E Rhodes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Hospital, University of Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre FranÃ§ais des Porphyries, HÃ´pital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <state>Cedex</state>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology , Heinrich-Heine-University Duesseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital, Department of Dermatology</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Woolos Hospital</name>
      <address>
        <city>Newport</city>
        <state>Wales</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Photobiology Unit - Hope Hospital, University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <results_first_submitted>September 16, 2021</results_first_submitted>
  <results_first_submitted_qc>September 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietic Protoporphyria</keyword>
  <keyword>EPP</keyword>
  <keyword>Afamelanotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afamelanotide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Afamelanotide</title>
          <description>administered afamelanotide implants on Days 0, 60, 120, 180 and 240.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>administered placebo implants on Days 0, 60, 120, 180 and 240.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Afamelanotide</title>
          <description>administered afamelanotide implants on Days 0, 60, 120, 180 and 240.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>administered placebo implants on Days 0, 60, 120, 180 and 240.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="13"/>
                    <measurement group_id="B2" value="38.6" spread="11.6"/>
                    <measurement group_id="B3" value="38.45" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)</title>
        <time_frame>From baseline to Day 270</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Afamelanotide</title>
            <description>administered afamelanotide implants on Days 0, 60, 120, 180 and 240.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>administered placebo implants on Days 0, 60, 120, 180 and 240.</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0" upper_limit="192.5"/>
                    <measurement group_id="O2" value="0.75" lower_limit="0" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Phototoxic Reactions</title>
        <time_frame>9 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Measured by Patient Completed Questionnaire</title>
        <time_frame>9 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Free Protoporphyrin IX Level</title>
        <time_frame>9 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Emergent Adverse Events</title>
        <time_frame>9 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Afamelanotide</title>
          <description>Afamelanotide implants administered on Days 0, 60, 120, 180 and 240.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo implants administered on Days 0, 60, 120, 180 and 240.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations Manager</name_or_title>
      <organization>CLINUVEL PHARMACEUTICALS LTD</organization>
      <email>mail@clinuvel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

